Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes.

Vaisar T, Kanter JE, Wimberger J, Irwin AD, Gauthier J, Wolfson E, Bahnam V, Wu IH, Shah H, Keenan HA, Greenbaum CJ, King GL, Heinecke JW, Bornfeldt KE.

Diabetes Care. 2019 Oct 9. pii: dc190772. doi: 10.2337/dc19-0772. [Epub ahead of print]

PMID:
31597668
2.

Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal Study.

Speake C, Bahnson HT, Wesley JD, Perdue N, Friedrich D, Pham MN, Lanxon-Cookson E, Kwok WW, Sehested Hansen B, von Herrath M, Greenbaum CJ.

Front Immunol. 2019 Sep 13;10:2023. doi: 10.3389/fimmu.2019.02023. eCollection 2019.

3.

Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention.

Sims EK, Geyer S, Johnson SB, Libman I, Jacobsen LM, Boulware D, Rafkin LE, Matheson D, Atkinson MA, Rodriguez H, Spall M, Larsson HE, Wherrett DK, Greenbaum CJ, Krischer J, DiMeglio LA; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2019 Sep 26. pii: dc190593. doi: 10.2337/dc19-0593. [Epub ahead of print]

PMID:
31558546
4.

In-vivo assessment of T cell kinetics in individuals at risk for type 1 diabetes.

Hao W, Bahnson HT, Speake C, Cerosaletti K, Greenbaum CJ.

Clin Exp Immunol. 2019 Sep 26. doi: 10.1111/cei.13375. [Epub ahead of print]

PMID:
31557315
5.

Abnormalities in proinsulin processing in islets from individuals with longstanding T1D.

Sims EK, Syed F, Nyalwidhe J, Bahnson HT, Haataja L, Speake C, Morris MA, Balamurugan AN, Mirmira RG, Nadler J, Mastracci TL, Arvan P, Greenbaum CJ, Evans-Molina C.

Transl Res. 2019 Nov;213:90-99. doi: 10.1016/j.trsl.2019.08.001. Epub 2019 Aug 9.

PMID:
31442418
6.

An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9.

PMID:
31180194
7.

Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes.

Acevedo-Calado MJ, Pietropaolo SL, Morran MP, Schnell S, Vonberg AD, Verge CF, Gianani R, Becker DJ, Huang S, Greenbaum CJ, Yu L, Davidson HW, Michels AW, Rich SS, Pietropaolo M; Type 1 Diabetes TrialNet Study Group.

Diabetes. 2019 Sep;68(9):1819-1829. doi: 10.2337/db18-1351. Epub 2019 Jun 5.

PMID:
31167877
8.

Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258-264.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C.

Diabetes Care. 2019 May;42(5):e85-e86. doi: 10.2337/dci19-0012. No abstract available.

PMID:
31010952
9.

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.

Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9.

PMID:
30967424
10.

Erratum. Genetics coming of age in type 1 diabetes. Diabetes Care 2019;42:189-191.

Cerosaletti K, Hao W, Greenbaum CJ.

Diabetes Care. 2019 May;42(5):987. doi: 10.2337/dc19-er05. Epub 2019 Mar 18. No abstract available.

11.

B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Speake C, Long SA, Dufort MJ.

JCI Insight. 2019 Feb 21;4(4). pii: 126136. doi: 10.1172/jci.insight.126136. eCollection 2019 Feb 21.

12.

Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.

Dufort MJ, Greenbaum CJ, Speake C, Linsley PS.

JCI Insight. 2019 Feb 21;4(4). pii: 125556. doi: 10.1172/jci.insight.125556. eCollection 2019 Feb 21.

13.

Genetics Coming of Age in Type 1 Diabetes.

Cerolsaletti K, Hao W, Greenbaum CJ.

Diabetes Care. 2019 Feb;42(2):189-191. doi: 10.2337/dci18-0039. No abstract available. Erratum in: Diabetes Care. 2019 May;42(5):987.

PMID:
30665964
14.

Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.

Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC; Immune Tolerance Network.

Diabetologia. 2019 Apr;62(4):655-664. doi: 10.1007/s00125-018-4786-9. Epub 2018 Dec 19.

PMID:
30569273
15.

Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes.

Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J, Mastracci TL, Marcovina S, Qian WJ, Yi L, Swensen AC, Yip-Schneider M, Schmidt CM, Considine RV, Arvan P, Greenbaum CJ, Evans-Molina C; T1D Exchange Residual C-peptide Study Group.

Diabetes Care. 2019 Feb;42(2):258-264. doi: 10.2337/dc17-2625. Epub 2018 Dec 10.

PMID:
30530850
16.

DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes.

James EA, Gillette L, Durinovic-Bello I, Speake C, Bondinas GP, Moustakas AK, Greenbaum CJ, Papadopoulos GK, Kwok WW.

J Immunol. 2018 Dec 15;201(12):3524-3533. doi: 10.4049/jimmunol.1800723. Epub 2018 Nov 19.

PMID:
30455401
17.

First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes.

Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, Davis A, Hodge KM, Bradfield JP, Zhou K, Guy VC, Åkerlund M, Wod M, Fritsche LG, Vestergaard H, Snyder J, Højlund K, Linneberg A, Käräjämäki A, Brandslund I, Kim CE, Witte D, Sørgjerd EP, Brillon DJ, Pedersen O, Beck-Nielsen H, Grarup N, Pratley RE, Rickels MR, Vella A, Ovalle F, Melander O, Harris RI, Varvel S, Grill VER; Bone Mineral Density in Childhood Study, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Åsvold BO, Yderstræde KB, Pearson ER, Schwartz S, Voight BF, Hansen T, Tuomi T, Boehm BO, Groop L, Leslie RD, Grant SFA.

Diabetes Care. 2018 Nov;41(11):2396-2403. doi: 10.2337/dc18-1032. Epub 2018 Sep 25.

PMID:
30254083
18.

Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes.

Cabrera SM, Engle S, Kaldunski M, Jia S, Geoffrey R, Simpson P, Szabo A, Speake C, Greenbaum CJ; Type 1 Diabetes TrialNet CTLA4-Ig (Abatacept) Study Group, Chen YG, Hessner MJ.

Diabetologia. 2018 Nov;61(11):2356-2370. doi: 10.1007/s00125-018-4708-x. Epub 2018 Aug 30.

19.

ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents.

Couper JJ, Haller MJ, Greenbaum CJ, Ziegler AG, Wherrett DK, Knip M, Craig ME.

Pediatr Diabetes. 2018 Oct;19 Suppl 27:20-27. doi: 10.1111/pedi.12734. No abstract available.

PMID:
30051639
20.

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.

Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group.

Diabetes Care. 2018 Sep;41(9):1917-1925. doi: 10.2337/dc18-0494. Epub 2018 Jul 16.

21.

Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.

Linsley PS, Greenbaum CJ, Rosasco M, Presnell S, Herold KC, Dufort MJ.

Genes Immun. 2019 Apr;20(4):293-307. doi: 10.1038/s41435-018-0032-1. Epub 2018 Jun 21.

22.

Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC, Atkinson MA.

Diabetes. 2018 Jul;67(7):1216-1225. doi: 10.2337/db18-0065. Epub 2018 May 16.

23.

Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.

Marre ML, McGinty JW, Chow IT, DeNicola ME, Beck NW, Kent SC, Powers AC, Bottino R, Harlan DM, Greenbaum CJ, Kwok WW, Piganelli JD, James EA.

Diabetes. 2018 Jul;67(7):1356-1368. doi: 10.2337/db17-1166. Epub 2018 Apr 13.

24.

Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.

Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ.

Diabetes Care. 2018 Apr;41(4):653-661. doi: 10.2337/dc17-0806.

25.

Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2018 Apr;41(4):913. doi: 10.2337/dc18-er04a. Epub 2018 Feb 23. No abstract available.

26.

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.

Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ.

JAMA. 2017 Nov 21;318(19):1891-1902. doi: 10.1001/jama.2017.17070.

27.

Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease.

Buckner JH, Greenbaum CJ.

J Immunol. 2017 Nov 1;199(9):3011-3013. doi: 10.4049/jimmunol.1701299. No abstract available.

28.

Assessment of β Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes.

Hao W, Woodwyk A, Beam C, Bahnson HT, Palmer JP, Greenbaum CJ.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4428-4434. doi: 10.1210/jc.2017-01713. Erratum in: J Clin Endocrinol Metab. 2018 Apr 1;103(4):1653.

29.

Erratum to: Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Dec;60(12):2540. doi: 10.1007/s00125-017-4446-5. No abstract available.

PMID:
28948305
30.

Understanding and preventing type 1 diabetes through the unique working model of TrialNet.

Battaglia M, Anderson MS, Buckner JH, Geyer SM, Gottlieb PA, Kay TWH, Lernmark Å, Muller S, Pugliese A, Roep BO, Greenbaum CJ, Peakman M.

Diabetologia. 2017 Nov;60(11):2139-2147. doi: 10.1007/s00125-017-4384-2. Epub 2017 Aug 2. Review. Erratum in: Diabetologia. 2017 Sep 26;:.

31.

Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes.

Cerosaletti K, Barahmand-Pour-Whitman F, Yang J, DeBerg HA, Dufort MJ, Murray SA, Israelsson E, Speake C, Gersuk VH, Eddy JA, Reijonen H, Greenbaum CJ, Kwok WW, Wambre E, Prlic M, Gottardo R, Nepom GT, Linsley PS.

J Immunol. 2017 Jul 1;199(1):323-335. doi: 10.4049/jimmunol.1700172. Epub 2017 May 31.

32.

Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes.

Yang J, Wen X, Xu H, Torres-Chinn N, Speake C, Greenbaum CJ, Nepom GT, Kwok WW.

J Immunol. 2017 Jul 1;199(1):91-96. doi: 10.4049/jimmunol.1601570. Epub 2017 May 26.

33.

Measurement of Pro-Islet Amyloid Polypeptide (1-48) in Diabetes and Islet Transplants.

Courtade JA, Klimek-Abercrombie AM, Chen YC, Patel N, Lu PYT, Speake C, Orban PC, Najafian B, Meneilly G, Greenbaum CJ, Warnock GL, Panagiotopoulos C, Verchere CB.

J Clin Endocrinol Metab. 2017 Jul 1;102(7):2595-2603. doi: 10.1210/jc.2016-2773.

PMID:
28368485
34.

Longitudinal monitoring of gene expression in ultra-low-volume blood samples self-collected at home.

Speake C, Whalen E, Gersuk VH, Chaussabel D, Odegard JM, Greenbaum CJ.

Clin Exp Immunol. 2017 May;188(2):226-233. doi: 10.1111/cei.12916. Epub 2017 Mar 2.

35.

Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Hundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH.

Sci Transl Med. 2016 Sep 14;8(356):356ra119. doi: 10.1126/scitranslmed.aad9943.

36.

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose.

Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2016 Oct;39(10):1664-70. doi: 10.2337/dc16-0360. Epub 2016 Jul 15.

37.

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.

Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19.

38.

Identification of tissue-specific cell death using methylation patterns of circulating DNA.

Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Hubert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1826-34. doi: 10.1073/pnas.1519286113. Epub 2016 Mar 14.

39.

NETosis-associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count.

Qin J, Fu S, Speake C, Greenbaum CJ, Odegard JM.

Clin Exp Immunol. 2016 Jun;184(3):318-22. doi: 10.1111/cei.12783. Epub 2016 Apr 13.

40.

Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.

Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ; Type 1 Diabetes TrialNet Canakinumab Study Group, Mandrup-Poulsen T; AIDA Study Group, Hessner MJ.

Eur J Immunol. 2016 Apr;46(4):1030-46. doi: 10.1002/eji.201546005. Epub 2016 Jan 21.

41.

Changing the Course of Disease in Type 1 Diabetes.

VanBuecken D, Lord S, Greenbaum CJ.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2018 Jun 11.

42.

Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2015 Oct;38(10):1975-85. doi: 10.2337/dc15-1429. Review.

43.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Review.

44.

Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic Controller.

Mauseth R, Lord SM, Hirsch IB, Kircher RC, Matheson DP, Greenbaum CJ.

J Diabetes Sci Technol. 2015 Sep 14;9(6):1253-9. doi: 10.1177/1932296815602098.

45.

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.

46.

Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?

Lord S, Greenbaum CJ.

Pharmacol Res. 2015 Aug;98:3-8. doi: 10.1016/j.phrs.2015.02.002. Epub 2015 Mar 11. Review.

47.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

48.

The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.

Hao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP.

Diabetes Care. 2015 May;38(5):891-6. doi: 10.2337/dc14-1825. Epub 2015 Feb 26.

49.

Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective.

Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Metab Res Rev. 2015 Sep;31(6):588-94. doi: 10.1002/dmrr.2643. Epub 2015 Apr 23.

50.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

Supplemental Content

Loading ...
Support Center